

11<sup>th</sup> June, 2024

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)- Update on Litigation**

Dear Sir/Madam,

In continuation of our earlier intimation dated 21<sup>st</sup> November, 2023, we wish to inform you that the petition filed under Section 9 of the Insolvency and Bankruptcy Code, 2016 by Piramal Critical Care, Inc., a step – down wholly owned subsidiary of Piramal Pharma Limited against Astral SteriTech Private Limited, a subsidiary of Centrient Pharmaceuticals has been admitted by Hon'ble National Company Law Tribunal, Ahmedabad Bench.

Request you to take the above on record.

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India  
T: +91 22 3802 3000 / 4000; Email: [shareholders.ppl@piramal.com](mailto:shareholders.ppl@piramal.com)

[piramalpharma.com](http://piramalpharma.com)